Get started
uniQure N.V.uniQure N.V.uniQure N.V.

uniQure N.V.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsForecastsSeasonalsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.35 B‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.111 CHF
Net income (FY)
‪−217.56 M‬ CHF
Revenue (FY)
‪24.63 M‬ CHF
Shares float
‪54.63 M‬
Beta (1Y)
0.76

Employees


Employees (FY)
209
Change (1Y)
−271 −56.46%
Revenue / Employee (1Y)
‪117.84 K‬ CHF
Net income / Employee (1Y)
‪−1.04 M‬ CHF

About uniQure N.V.


Sector
Health Technology
Industry
Biotechnology
CEO
Matthew C. Kapusta
Website
uniqure.com
Headquarters
Amsterdam
Founded
2012
ISIN
NL0010696654
FIGI
BBG00LVGHR41
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

Check out other big names from the same industry as UQ1.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs


XBI
SPDR S&P BIOTECH ETF
Weight
1.14%
Market value
‪77.75 M‬
USD
VXF
Vanguard Extended Market ETF
Weight
0.04%
Market value
‪37.92 M‬
USD
SCHA
Schwab U.S. Small-Cap ETF
Weight
0.11%
Market value
‪19.86 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.30%
Market value
‪19.62 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.04%
Market value
‪6.84 M‬
USD
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Weight
1.65%
Market value
‪6.24 M‬
USD
KOMP
SPDR S&P Kensho New Economies Composite ETF
Weight
0.10%
Market value
‪2.42 M‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.32%
Market value
‪2.36 M‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.32%
Market value
‪2.36 M‬
USD
GNOM
Global X Genomics & Biotechnology ETF
Weight
3.31%
Market value
‪1.80 M‬
USD
PRFZ
Invesco RAFI US 1500 Small-Mid ETF
Weight
0.07%
Market value
‪1.68 M‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of UQ1 is 48.678 CHF — it has decreased by −6.70% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange uniQure N.V. stocks are traded under the ticker UQ1.
We've gathered analysts' opinions on uniQure N.V. future price: according to them, UQ1 price has a max estimate of 87.87 CHF and a min estimate of 44.73 CHF. Watch UQ1 chart and read a more detailed uniQure N.V. stock forecast: see what analysts think of uniQure N.V. and suggest that you do with its stocks.
UQ1 reached its all-time high on Oct 10, 2025 with the price of 52.173 CHF, and its all-time low was 4.302 CHF and was reached on May 29, 2024. View more price dynamics on UQ1 chart.
See other stocks reaching their highest and lowest prices.
UQ1 stock is 7.18% volatile and has beta coefficient of 0.76. Track uniQure N.V. stock price on the chart and check out the list of the most volatile stocks — is uniQure N.V. there?
Today uniQure N.V. has the market capitalization of ‪3.35 B‬, it has increased by 7.82% over the last week.
Yes, you can track uniQure N.V. financials in yearly and quarterly reports right on TradingView.
uniQure N.V. is going to release the next earnings report on Nov 3, 2025. Keep track of upcoming events with our Earnings Calendar.
UQ1 earnings for the last quarter are −0.55 CHF per share, whereas the estimation was −0.71 CHF resulting in a 22.89% surprise. The estimated earnings for the next quarter are −0.72 CHF per share. See more details about uniQure N.V. earnings.
uniQure N.V. revenue for the last quarter amounts to ‪4.17 M‬ CHF, despite the estimated figure of ‪4.28 M‬ CHF. In the next quarter, revenue is expected to reach ‪4.23 M‬ CHF.
UQ1 net income for the last quarter is ‪−29.93 M‬ CHF, while the quarter before that showed ‪−38.63 M‬ CHF of net income which accounts for 22.53% change. Track more uniQure N.V. financial stats to get the full picture.
No, UQ1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2025, the company has 209 employees. See our rating of the largest employees — is uniQure N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. uniQure N.V. EBITDA is ‪−130.50 M‬ CHF, and current EBITDA margin is −632.89%. See more stats in uniQure N.V. financial statements.
Like other stocks, UQ1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade uniQure N.V. stock right from TradingView charts — choose your broker and connect to your account.